Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients

Type Journal Article Author Sharon Amit Author Gili Regev-Yochay Author Arnon Afek Author Yitshak Kreiss Author Eyal Leshem URL https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00448-7/abstract Volume 397 Issue 10277 Pages 875-877 Publication The Lancet ISSN 0140-6736, 1474-547X Date 18/02/2021 Extra Publisher: Elsevier PMID: 33610193 Journal Abbr The Lancet DOI 10.1016/S0140-6736(21)00448-7 Library Catalog www.thelancet.com Language English Abstract In December, 2020, the Israeli Government approved the BNT162b2 COVID-19 vaccine and initiated a national immunisation campaign prioritising health-care workers (HCWs), as in other countries.1 This campaign coincided with a third wave of COVID-19, peaking at 10 116 daily new cases by mid-January, 2021. The Sheba Medical Centre, Israel's largest hospital with 9647 HCWs, began staff vaccination on Dec 19, 2020. All HCWs, excluding those with previous SARS-CoV-2 infection, were eligible for vaccination.